PT975597E - Derivados de quinoleínas enquanto inibidores da vih integrase - Google Patents

Derivados de quinoleínas enquanto inibidores da vih integrase Download PDF

Info

Publication number
PT975597E
PT975597E PT98920581T PT98920581T PT975597E PT 975597 E PT975597 E PT 975597E PT 98920581 T PT98920581 T PT 98920581T PT 98920581 T PT98920581 T PT 98920581T PT 975597 E PT975597 E PT 975597E
Authority
PT
Portugal
Prior art keywords
aryl
group
different
alkyl
substituents
Prior art date
Application number
PT98920581T
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Auclair
Khalid Mekouar
Jean D Angelo
Didier Desmaele
Jean-Francois Mouscadet
Frederic Subra
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient filed Critical Roussy Inst Gustave
Publication of PT975597E publication Critical patent/PT975597E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT98920581T 1997-04-08 1998-04-07 Derivados de quinoleínas enquanto inibidores da vih integrase PT975597E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9704289A FR2761687B1 (fr) 1997-04-08 1997-04-08 Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques

Publications (1)

Publication Number Publication Date
PT975597E true PT975597E (pt) 2010-01-04

Family

ID=9505648

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98920581T PT975597E (pt) 1997-04-08 1998-04-07 Derivados de quinoleínas enquanto inibidores da vih integrase

Country Status (12)

Country Link
US (1) US6670377B1 (enExample)
EP (1) EP0975597B1 (enExample)
JP (1) JP4697679B2 (enExample)
AT (1) ATE441634T1 (enExample)
CA (1) CA2286385C (enExample)
CY (1) CY1109553T1 (enExample)
DE (1) DE69841119D1 (enExample)
DK (1) DK0975597T3 (enExample)
ES (1) ES2332434T3 (enExample)
FR (1) FR2761687B1 (enExample)
PT (1) PT975597E (enExample)
WO (1) WO1998045269A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321348A1 (en) * 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
FR2819507B1 (fr) 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
WO2002070486A1 (en) 2001-03-01 2002-09-12 Shionogi & Co., Ltd. Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
FR2830863B1 (fr) * 2001-10-12 2004-01-30 Bioalliance Pharma Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives
FR2839646B1 (fr) * 2002-05-17 2008-04-11 Bioalliance Pharma Utilisation de derives de quinoleine a effet anti-integrase et ses applications
AU2003257822A1 (en) 2002-08-13 2004-04-30 Shionogi And Co., Ltd. Heterocyclic compound having hiv integrase inhibitory activity
RU2275361C3 (ru) * 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
AR042095A1 (es) 2002-11-20 2005-06-08 Japan Tobacco Inc Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
KR100866296B1 (ko) * 2004-05-20 2008-11-11 니뽄 다바코 산교 가부시키가이샤 4―옥소퀴놀린 화합물의 안정한 결정체
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2006129134A1 (en) * 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents
AU2007223260C1 (en) 2006-03-06 2011-02-03 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
CN103450077B (zh) * 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
RU2503679C2 (ru) * 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8377960B2 (en) * 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2009062285A1 (en) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705338A1 (en) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2149557A1 (en) * 2008-07-23 2010-02-03 BioAlliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
EP2147912A1 (en) 2008-07-23 2010-01-27 BioAlliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
EP2147913A1 (en) 2008-07-23 2010-01-27 BioAlliance Pharma Styrylquinolines, their process of preparation and their therapeutic uses
WO2012003498A1 (en) * 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
CA2860015C (en) 2011-12-22 2020-07-07 Universite Laval Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1)
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
AU2019344897B2 (en) 2018-09-18 2024-01-18 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152891A (ja) 1983-02-18 1984-08-31 Yamada Kagaku Kogyo Kk 発色性記録材料
EP0206751A3 (en) * 1985-06-18 1988-05-25 Merck Frosst Canada Inc. 2-substituted quinolines, their preparation and use
EP0219307A3 (en) 1985-10-16 1987-10-14 Merck Frosst Canada Inc. 2-substituted quinolines
JPS61189988A (ja) 1986-08-11 1986-08-23 Yamada Kagaku Kogyo Kk 発色性記録材料
JPH01199979A (ja) * 1987-04-07 1989-08-11 Kanebo Ltd 新規キノリンカルボン酸誘導体および該化合物を有効成分とする抗菌剤
IL88433A0 (en) 1987-11-25 1989-06-30 Merck Frosst Canada Inc Diarylstyrylquinoline diacids and pharmaceutical compositions containing them
US5438141A (en) 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
EP0643045B1 (de) 1993-09-10 2000-03-08 Novartis AG Chinolin-Verbindungen als Leukotriene Antagonisten
GB9414590D0 (en) 1994-07-20 1994-09-07 Leo Pharm Prod Ltd Chemical compounds
ES2103180B1 (es) 1994-08-01 1998-04-01 Menarini Lab Fenilacetamidas con accion antagonista de los leucotrienos.
EP0725063A1 (de) 1995-02-01 1996-08-07 Ciba-Geigy Ag Chinolin-Derivate
AU4172197A (en) * 1996-09-10 1998-04-02 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents

Also Published As

Publication number Publication date
FR2761687B1 (fr) 2000-09-15
US6670377B1 (en) 2003-12-30
ES2332434T3 (es) 2010-02-04
WO1998045269A1 (fr) 1998-10-15
CA2286385A1 (fr) 1998-10-15
CY1109553T1 (el) 2014-08-13
EP0975597B1 (fr) 2009-09-02
JP2001518890A (ja) 2001-10-16
DE69841119D1 (de) 2009-10-15
EP0975597A1 (fr) 2000-02-02
DK0975597T3 (da) 2009-11-02
CA2286385C (fr) 2011-02-01
ATE441634T1 (de) 2009-09-15
FR2761687A1 (fr) 1998-10-09
JP4697679B2 (ja) 2011-06-08

Similar Documents

Publication Publication Date Title
PT975597E (pt) Derivados de quinoleínas enquanto inibidores da vih integrase
WO2000010965A3 (en) Quaternary ammonium salts and their use as anti-hiv agents
PT87700A (pt) Process for the preparation of a new pyrazolopyridine compound
MX9504349A (es) Derivados de aroilpiperidina.
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
DK0799833T3 (da) Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
HRP20010573B1 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
HUP9802315A2 (hu) Trombin inhibitorok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
WO2003068750A1 (en) Jnk inhibitor
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
DK0916646T3 (da) Fremgangsmåde til fremstillingen af en substitueret 2,5-diamino-3-hydroxyhexan
NO912805L (no) Fremgangsmaate for fremstilling av pyrazolopyridin-forbindelser.
WO1999000373A8 (en) Benzimidazole derivatives
DK0513675T3 (da) Hidtil ukendt peptidforbindelse samt fremgangsmåde til fremstilling deraf
EP0713870A4 (en) NEW FUSED INDANE DERIVATIVE AND SALT OF SAID PHARMACEUTICALLY ACCEPTABLE DERIVATIVE
FI940229A0 (fi) Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
WO1997031016A3 (en) New inhibitors of sh2-mediated processes
NO973213L (no) Nye 2-(1H)-quinolinforbindelser, fremgangsmåter ved fremstilling av slike samt farmasöytiske sammensetninger omfattende disse
CA2015730A1 (en) Esters of phenylalkanoic acid
DK0855398T3 (da) Sesquiterpenderivater med antiviral aktivitet
YU200791A (sh) Trifluorometil 1-karba (1-detia) cefemi
EP1445262A4 (en) PEPTIDE DERIVATIVE, PHARMACEUTICALLY SALT SUBSTANTIAL, METHOD FOR ITS PREPARATION AND ITS USE
EP0260605A3 (en) Dihydropyridine-5-phosphonic acid cyclic ester
WO2000050017A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
TH65070A (enExample)